StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.0
Power Rank trend -> Rising
07/26/2024 16:00:00 EST
Maravai Lifesciences Holdings Inc (MRVI)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, MRVI has been trading in a range between $9.29 and $6.84 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
MRVI is trading below resistance at $11.34, about 24% to the upside. There is support at $8.52 -7% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Maravai Lifesciences Holdings Inc $MRVI entered a Green zone 12 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $13, a potential upside of 41.92% from the recent price of 9.16. The stock is trading 32.21% (potential upside) below its 52 week high of $12.11 and 102.65 % (potential downside) above its 52 week low of $4.52 - based on the recent price.
Company Summary
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
News
| Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024 SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on Wednesday, August 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. Source: GlobeNewsWire Wed, 10 Jul 2024 08:00:00 -0400 Sentiment: Neutral |
| Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report - Highlights progress across four priority areas and commitment to environmentally and socially responsible growth. Source: GlobeNewsWire Tue, 02 Jul 2024 16:00:00 -0400 Sentiment: Neutral |
| Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics - Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability - - Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand - STONY BROOK, NY AND JUPITER, FL / ACCESSWIRE / June 20, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company (NASDAQ:MRVI) and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of the companies' previously announced Linea™ RNAP manufacturing scale-up agreement. The joint process development project resulted in an over 70% reduction in Linea RNAP manufacturing costs and the manufacture of a quantity of Linea RNAP sufficient to support Applied DNA's anticipated near-term demand for critical starting material for mRNA production. Source: Accesswire Thu, 20 Jun 2024 09:15:00 -0400 Sentiment: Neutral |
| Maravai (MRVI) Advances in RNA Research With New Collaboration Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies. Source: Zacks Investment Research Fri, 17 May 2024 12:56:05 -0400 Sentiment: Positive |
| TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink's leading RNA synthesis technology. TriLink's investment inclu. Source: Business Wire Mon, 13 May 2024 08:00:00 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 12.105 52 Week Low: 4.52 Beta: 0.015 50 Day MA: 8.5836 200 Day MA: 7.3096 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.327 Qtr Revenue Growth YOY: -0.188 Forward PE: 30.3951 Trailing PE: 0